Israel Englander Madrigal Pharmaceuticals, Inc. Call Options Transaction History

Millennium Management LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$193.33 - $291.99 $2.86 Million - $4.32 Million	14,800 Added 1644.44%	15,700 $4.4 Million
Q1 2024 May 15, 2024	SELL	$171.37 - $283.23 $102,822 - $169,938	-600 Reduced 40.0%	900 $240,000
Q4 2023 Feb 14, 2024	SELL	$120.4 - $237.13 $48,160 - $94,852	-400 Reduced 21.05%	1,500 $347,000
Q2 2023 Aug 14, 2023	SELL	$203.88 - $312.0 $3.2 Million - $4.9 Million	-15,700 Reduced 89.2%	1,900 $438,000
Q1 2023 May 15, 2023	SELL	$231.06 - $307.08 $8.71 Million - $11.6 Million	-37,700 Reduced 68.17%	17,600 $4.26 Million
Q4 2022 Feb 14, 2023	BUY	$58.39 - $296.54 $3.23 Million - $16.4 Million	55,300 New	55,300 $16.1 Million

296

22M

819K

640K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.63B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.